Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 10/20 | 0.79 |
| ▸ | ALPL | P05186 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 2/20 | 0.51 |
| ▸ | ALPG | P10696 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223356 | 1.00 | CCR3 (0.79) | CCR3ALPLALPIALPGTP53 | |
| SCHEMBL5742843 | 0.92 | CCR3 (0.67) | CCR3ALPLALPIALPGTP53 | |
| SCHEMBL5742848 | 0.92 | CCR3 (0.67) | CCR3ALPLALPIALPGTP53 | |
| Iodide SCHEMBL7868477 | 0.92 | CCR3 (0.74) | CCR3ALPLALPIALPGTP53 | |
| SCHEMBL5854102 | 0.90 | CCR3 (0.66) | CCR3ALPLALPIALPGTP53 | |
| SCHEMBL5854109 | 0.90 | CCR3 (0.66) | CCR3ALPLALPIALPGTP53 | |
| Hydrochloric Acid SCHEMBL5744004 | 0.90 | CCR3 (0.63) | CCR3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5744002 | 0.90 | CCR3 (0.63) | CCR3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5855327 | 0.90 | CCR3 (0.63) | CCR3MEN1KMT2A | |
| SCHEMBL7865818 | 0.89 | CCR3 (0.76) | CCR3ALPLALPIALPGTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | GONG LEYI (US) | 2004-12-30 | — | — | US | claimed |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | ROCHE BIOSCIENCE | 2003-08-14 | — | — | US | claimed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| EP-2498775-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | Almirall S.A. (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| EP-2146988-B1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011057757-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-05-19 | — | — | WO | disclosed |
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | GONG LEYI (US) | 2004-12-30 | — | — | US | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6683074-B1 | PYRROLIDINYL, PIPERAZINYL AND AZEPINYL DERIVATIVES; INFLAMMATORY OR ALLERGIC DISEASES | SYNTEX (U.S.A.) LLC | 2004-01-27 | — | — | US | disclosed |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | ROCHE BIOSCIENCE | 2003-08-14 | — | — | US | disclosed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | disclosed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | CCR3 1/4885ALPL 4885/4885ALPI 4236/4885 |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | CCR3 1/4885ALPL 4885/4885ALPI 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.